LBH Phase II in Small Cell Lung Cancer (SCLC)

Status Completed

Clinical Trial Summary

SCLC is the most aggressive and lethal form of lung cancer, typically very sensitive to cytotoxic therapy when first diagnosed, but associated with a high incidence of tumour relapse and a very poor life expectancy. Combination chemotherapy based on cisplatin or carboplatin and etoposide represents the most widely used regimen. Despite of the high response rate, approximately 80% of patients with limited disease and nearly all patients with extended disease develop disease relapse or progression. Topotecan is, at present, the only approved second line treatment in Europe.

The search of a new therapeutic agent that could alter the natural history of SCLC would be an important goal to be reached. LBH589 (Panobinostat) is a histone deacetylase (HDAC) inhibitor available for intravenous and oral administration. LBH589 could be classified as PAN-DAC inhibitor targeting both histone and non histone proteins and as such it could be suitable for combination with cytotoxics. Three phase I dose escalation studies with both the intravenous and the oral formulation of LBH589, examining various dose schedules of administration have been conducted in advanced solid tumours and haematological malignancies.

Single agent activity was observed in phase I in patients with haematological cancer. In solid tumours one response (Hormone-refractory Prostatic Cancer) and some prolonged stabilizations have been observed with intravenous formulation. Phase II studies are now in progress.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01222936
Study type	Interventional
Source	Southern Europe New Drug Organization
Contact
Status	Completed
Phase	Phase 2
Start date	May 2008
Completion date	August 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05882058` - DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers	Phase 2
Terminated	`NCT03963414` - A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC	Phase 1
Active, not recruiting	`NCT04358237` - Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.	Phase 1/Phase 2
Not yet recruiting	`NCT06419179` - Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)	Phase 2
Completed	`NCT02874664` - A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer	Phase 1
Completed	`NCT02397733` - Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)	N/A
Recruiting	`NCT01977235` - Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer	Phase 2
Completed	`NCT00759824` - A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide	Phase 2
Active, not recruiting	`NCT03568097` - Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer	Phase 2
Withdrawn	`NCT02876081` - Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex	Phase 2
Recruiting	`NCT06247605` - A Phase IIII Study of AL8326 in Small Cell Lung Cancer	Phase 3
Recruiting	`NCT04996771` - Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer	Phase 1/Phase 2
Terminated	`NCT03662074` - Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer	Phase 2
Completed	`NCT03232593` - A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Completed	`NCT01941316` - Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients	Phase 1/Phase 2
Terminated	`NCT01574300` - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Recruiting	`NCT06131840` - A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05683977` - A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Recruiting	`NCT04620837` - Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy	Phase 2
Recruiting	`NCT05329623` - A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.	Phase 1